Hemocit-P 500mg/400mg Tablet is a combination pharmaceutical formulation containing Citicoline 500mg and Piracetam 400mg, indicated for the management of cognitive impairments and neurological disorders. Citicoline, a neuroprotective agent, plays a crucial role in enhancing cerebral metabolism by promoting the synthesis of phosphatidylcholine, a vital component of neuronal membranes, thereby supporting membrane repair and neuroplasticity. Piracetam, a nootropic agent, modulates neurotransmission and improves microcirculation in the brain, which contributes to enhanced cognitive function, memory, and learning capacity. The synergistic effect of these two active ingredients makes Hemocit-P effective in treating conditions such as stroke recovery, traumatic brain injury, dementia, and other cognitive dysfunctions. It is also used as an adjunct therapy in managing age-related cognitive decline and neurodegenerative diseases. Hemocit-P is generally well-tolerated, with a favorable safety profile; however, it should be used under medical supervision, especially in patients with a history of bleeding disorders or renal impairment. Dosage and duration of therapy should be individualized based on clinical response and patient tolerance. Regular monitoring and consultation with a healthcare professional are recommended to optimize therapeutic outcomes and minimize potential adverse effects.